Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Psoriasis: HELP
Articles from Leicester
Based on 9 articles published since 2010

These are the 9 published articles about Psoriasis that originated from Leicester during 2010-2020.
+ Citations + Abstracts
1 Review Expanding the applications of microneedles in dermatology. 2019

Sabri, Akmal H / Ogilvie, Jane / Abdulhamid, Khuriah / Shpadaruk, Volha / McKenna, John / Segal, Joel / Scurr, David J / Marlow, Maria. ·Division of Advanced Materials and Healthcare Technologies, School of Pharmacy, The University of Nottingham, NG7 2RD, UK. · Walgreens Boots Alliance, Thane Road, Nottingham NG90 1BS, UK. · Division of Advanced Materials and Healthcare Technologies, School of Pharmacy, The University of Nottingham, NG7 2RD, UK; Department of Pharmaceutics, Faculty of Pharmacy, UiTM Puncak Alam Campus, 42300 Bandar Puncak Alam, Selangor, Malaysia. · Leicester Royal Infirmary University Hospitals Leicester Dermatology Department, Infirmary Square, Leicester LE1 5WW, UK. · Department of Mechanical, Materials and Manufacturing Engineering, Faculty of Engineering, University of Nottingham, Nottingham NG8 1BB, UK. · Division of Advanced Materials and Healthcare Technologies, School of Pharmacy, The University of Nottingham, NG7 2RD, UK. Electronic address: Maria.Marlow@nottingham.ac.uk. ·Eur J Pharm Biopharm · Pubmed #31059780.

ABSTRACT: Since the first patent for microneedles was filed in the 1970s, research on utilising microneedles as a drug delivery system has progressed significantly. In addition to the extensive research on microneedles for improving transdermal drug delivery, there is a growing interest in using these devices to manage dermatological conditions. This review aims to provide the background on microneedles, the clinical benefits, and challenges of the device along with the potential dermatological conditions that may benefit from the application of such a drug delivery system. The first part of the review provides an outline on benefits and challenges of translating microneedle-based drug delivery systems into clinical practice. The second part of the review covers the application of microneedles in treating dermatological conditions. The efficacy of microneedles along with the limitations of such a strategy to treat diseased skin shall be addressed.

2 Review An evolutionary history of defensins: a role for copy number variation in maximizing host innate and adaptive immune responses. 2015

Machado, Lee R / Ottolini, Barbara. ·Institute of Health and Wellbeing, School of Health, University of Northampton , Northampton , UK. · Department of Cancer Studies, University of Leicester , Leicester , UK. ·Front Immunol · Pubmed #25852686.

ABSTRACT: Defensins represent an evolutionary ancient family of antimicrobial peptides that play diverse roles in human health and disease. Defensins are cationic cysteine-containing multifunctional peptides predominantly expressed by epithelial cells or neutrophils. Defensins play a key role in host innate immune responses to infection and, in addition to their classically described role as antimicrobial peptides, have also been implicated in immune modulation, fertility, development, and wound healing. Aberrant expression of defensins is important in a number of inflammatory diseases as well as modulating host immune responses to bacteria, unicellular pathogens, and viruses. In parallel with their role in immunity, in other species, defensins have evolved alternative functions, including the control of coat color in dogs. Defensin genes reside in complex genomic regions that are prone to structural variations and some defensin family members exhibit copy number variation (CNV). Structural variations have mediated, and continue to influence, the diversification and expression of defensin family members. This review highlights the work currently being done to better understand the genomic architecture of the β-defensin locus. It evaluates current evidence linking defensin CNV to autoimmune disease (i.e., Crohn's disease and psoriasis) as well as the contribution CNV has in influencing immune responses to HIV infection.

3 Review Palmoplantar pustulosis secondary to rituximab: a case report and literature review. 2015

Venables, Z C / Swart, S S / Soon, C S. ·Dermatology Department, Leicester Royal Infirmary, Leicester, UK. zoevenables@hotmail.co.uk. · Haematology Department, Northampton General Hospitals NHS Trust, Cliftonville, Northampton, NN1 5BD, UK. · Dermatology Department, Leicester Royal Infirmary, Leicester, UK. ·Clin Exp Dermatol · Pubmed #25511468.

ABSTRACT: -- No abstract --

4 Article Luteolin-7-glucoside inhibits IL-22/STAT3 pathway, reducing proliferation, acanthosis, and inflammation in keratinocytes and in mouse psoriatic model. 2016

Palombo, R / Savini, I / Avigliano, L / Madonna, S / Cavani, A / Albanesi, C / Mauriello, A / Melino, G / Terrinoni, A. ·Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Via Montpellier, 1, Rome 00133, Italy. · Experimental Immunology Laboratory, Biochemistry Laboratory, IDI-IRCCS-FLMM, Via dei Monti di Creta, 104, Rome 00167, Italy. · Department Biomedicine and Prevention, University of Rome "Tor Vergata", Via Montpellier, 1, Rome 00133, Italy. · Medical Research Council, Toxicology Unit, Hodgkin Building, Leicester University, Lancaster Road, P.O. Box 138, Leicester LE1 9HN, UK. · Biochemistry Laboratory, IDI-IRCCS-FLMM, Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Via Montpellier, 1, Rome 00133, Italy. ·Cell Death Dis · Pubmed #27537526.

ABSTRACT: The epidermis is a dynamic tissue in which keratinocytes proliferate in the basal layer and undergo a tightly controlled differentiation while moving into the suprabasal layers. The balance between keratinocyte proliferation, differentiation, and death is essential, and its perturbation can result in pathological changes. Some common skin diseases, such as psoriasis, are characterized by hyperproliferation accompanied by inflammatory reactions, suggesting that molecules with topical anti-inflammatory and ROS scavenging abilities may be useful for their treatment. Here we investigate the potential of the flavone Luteolin-7-glucoside (LUT-7G) as a treatment for psoriasis. We show that LUT-7G leads to a modification of the cell cycle and the induction of keratinocyte differentiation, with modification of energy, fatty acid, and redox metabolism. LUT-7G treatment also neutralizes the proliferative stimulus induced by the proinflammatory cytokines IL-22 and IL-6 in HEKn. Moreover, in the Imiquimod (IMQ) mouse model of psoriasis, topical administration of LUT-7G leads to a marked reduction of acanthosis and re-expression of epidermal differentiation markers. Dissection of the IL-22 signalling pathway, activated by IMQ treatment, demonstrates that LUT-7G impairs the nuclear translocation of phosphorylated (activated) STAT3, blocking the IL-22 signalling cascade. Thus LUT-7G appears to be a promising compound for the treatment of hyperproliferative and inflammatory skin diseases, such as psoriasis.

5 Article Psoriasis. 2012

Stollery, Nigel. ·Leicester Royal Infirmary, Leicester, UK. ·Practitioner · Pubmed #22988704.

ABSTRACT: -- No abstract --

6 Article Development of a transparent interactive decision interrogator to facilitate the decision-making process in health care. 2011

Bujkiewicz, Sylwia / Jones, Hayley E / Lai, Monica C W / Cooper, Nicola J / Hawkins, Neil / Squires, Hazel / Abrams, Keith R / Spiegelhalter, David J / Sutton, Alex J. ·Department of Health Sciences, University of Leicester, Leicester, UK. sb309@leicester.ac.uk ·Value Health · Pubmed #21839417.

ABSTRACT: BACKGROUND: Decisions about the use of new technologies in health care are often based on complex economic models. Decision makers frequently make informal judgments about evidence, uncertainty, and the assumptions that underpin these models. OBJECTIVES: Transparent interactive decision interrogator (TIDI) facilitates more formal critique of decision models by decision makers such as members of appraisal committees of the National Institute for Health and Clinical Excellence in the UK. By allowing them to run advanced statistical models under different scenarios in real time, TIDI can make the decision process more efficient and transparent, while avoiding limitations on pre-prepared analysis. METHODS: TIDI, programmed in Visual Basic for applications within Excel, provides an interface for controlling all components of a decision model developed in the appropriate software (e.g., meta-analysis in WinBUGS and the decision model in R) by linking software packages using RExcel and R2WinBUGS. TIDI's graphical controls allow the user to modify assumptions and to run the decision model, and results are returned to an Excel spreadsheet. A tool displaying tornado plots helps to evaluate the influence of individual parameters on the model outcomes, and an interactive meta-analysis module allows the user to select any combination of available studies, explore the impact of bias adjustment, and view results using forest plots. We demonstrate TIDI using an example of a decision model in antenatal care. CONCLUSION: Use of TIDI during the NICE appraisal of tumor necrosis factor-alpha inhibitors (in psoriatic arthritis) successfully demonstrated its ability to facilitate critiques of the decision models by decision makers.

7 Article Scalp problems. 2010

Stollery, Nigel. ·Leicester Royal Infirmary. ·Practitioner · Pubmed #20307029.

ABSTRACT: -- No abstract --

8 Minor How are we using systemic drugs to treat psoriasis in children? An insight into current clinical U.K. practice. 2015

Burden-Teh, E / Lam, M L / Taibjee, S M / Taylor, A / Webster, S / Dolman, S / Jury, C / Caruana, D / Darne, S / Carmichael, A / Natarajan, S / McPherson, T / Moore, A / Katugampola, R / Kalavala, M / Al-Ismail, D / Richards, L / Jones, V / Batul Syed, S / Glover, M / Hughes, J / Anderson, E / Hughes, B / Helbling, I / Murphy, R. ·Department of Dermatology, Nottingham University Hospitals Trust, Nottingham, U.K. esther.burden-teh@nottingham.ac.uk. · Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, U.K. esther.burden-teh@nottingham.ac.uk. · Department of Dermatology, Nottingham University Hospitals Trust, Nottingham, U.K. · Department of Dermatology, Dorset County Hospital, Dorset, U.K. · Department of Dermatology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, U.K. · Department of Dermatology, Alder Hey Children's Hospital, West Derby, U.K. · Department of Dermatology, Royal Hospital for Sick Children, Glasgow, U.K. · Department of Dermatology, The James Cook University Hospital, Middlesbrough, U.K. · Department of Dermatology, Churchill Hospital, Oxford, U.K. · Department of Dermatology, University Hospital Wales, Cardiff, U.K. · Department of Dermatology, Royal Cornwall Hospital NHS Trust, Cornwall, U.K. · Department of Dermatology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, U.K. · Department of Dermatology, Princess of Wales Hospital, Bridgend, U.K. · Department of Dermatology, Portsmouth Hospitals NHS Trust, Portsmouth, U.K. · Department of Dermatology, St Richards Hospital, Chichester, U.K. · Department of Dermatology, University Hospitals of Leicester, Leicester, UK. ·Br J Dermatol · Pubmed #25601323.

ABSTRACT: -- No abstract --

9 Unspecified Psoriasis: an evidence-based update. Report of the 9th evidenced based update meeting, 12 May 2011, Loughborough, UK. 2012

De Mozzi, P / Johnston, G A / Alexandroff, A B. ·Department of Dermatology, Leicester Royal Infirmary, Leicester LE1 5WW, UK. ·Br J Dermatol · Pubmed #22268857.

ABSTRACT: The Centre of Evidence Based Dermatology, University of Nottingham, U.K. holds an annual Evidence Based Update (EBU) Meeting focused on important dermatological topics, which have in the past included eczema, urticaria, blistering disorders, skin infections, skin cancer and hair disorders. These one-day meetings aim to summarize the most recent evidence in the form of systematic reviews and recently completed clinical trials. This year, the 9th EBU meeting took place in Loughborough, U.K. on 12 May 2011 and was devoted to psoriasis. The latest updates on topical treatments, nail psoriasis, genetics and clinical implications, rational use of biologics, new and unpublished studies on combination of phototherapy and biologics for psoriasis, and on treatments of palmoplantar pustular psoriasis were discussed by a panel of renowned international speakers.